Medicus Pharma (NASDAQ:MDCX) Cut to Strong Sell at Wall Street Zen

Wall Street Zen downgraded shares of Medicus Pharma (NASDAQ:MDCX) from a sell rating to a strong sell rating in a research note released on Sunday morning,Wall Street Zen reports.

Several other equities analysts have also issued reports on MDCX. Weiss Ratings upgraded Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Alliance Global Partners reiterated a “buy” rating on shares of Medicus Pharma in a research report on Monday, September 14th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $450.00.

Medicus Pharma Trading Down 2.9%

Shares of NASDAQ:MDCX opened at $1.83 on Friday. The stock’s 50-day moving average price is $5.69 and its 200-day moving average price is $21.07. Medicus Pharma has a 12-month low of $1.70 and a 12-month high of $127.50. The stock has a market capitalization of $2.31 million, a P/E ratio of -0.02 and a beta of 0.80.

Medicus Pharma (NASDAQ:MDCX) last released its earnings results on Friday, November 6th. The company reported ($11.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($8.50) by ($3.14). As a group, research analysts predict that Medicus Pharma will post -33.50 EPS for the current year.

Institutional Investors Weigh In On Medicus Pharma

A number of large investors have recently added to or reduced their stakes in the company. Interchange Capital Partners LLC raised its stake in shares of Medicus Pharma by 33.9% during the third quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock valued at $343,000 after acquiring an additional 538,039 shares during the last quarter. Private Advisor Group LLC boosted its holdings in shares of Medicus Pharma by 36.8% during the first quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock worth $110,000 after purchasing an additional 64,560 shares during the period. Finally, Sterling Investment Advisors Ltd. bought a new stake in shares of Medicus Pharma in the second quarter worth about $45,000.

About Medicus Pharma

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes. Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.